Mycenax Biotech Inc. (TPEX:4726)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
25.20
+0.30 (1.20%)
Jun 18, 2026, 1:30 PM CST
Market Cap5.22B -37.1%
Revenue (ttm)815.34M +12.4%
Net Income-436.48M
EPS-2.11
Shares Out 207.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume168,151
Open24.90
Previous Close24.90
Day's Range24.90 - 25.45
52-Week Range24.55 - 41.20
Beta0.39
AnalystsHold
Price Target58.00 (+130.16%)
Earnings DateAug 10, 2026

About Mycenax Biotech

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, and quality services. It also offers bispecific antibody production, and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 387
Stock Exchange Taipei Exchange
Ticker Symbol 4726
Full Company Profile

Financial Performance

In 2025, Mycenax Biotech's revenue was 740.24 million, an increase of 8.23% compared to the previous year's 683.92 million. Losses were -448.63 million, -3.96% less than in 2024.

Financial Statements